全球棕榈酰乙醇酰胺市场规模（按类型、应用、区域范围和预测）

棕榈酰乙醇酰胺市场规模及预测

预计 2024 年棕榈酰乙醇酰胺 (PEA) 市场规模将达到 1,342 亿美元，到 2032 年将达到 2,574 亿美元，2026 年至 2032 年的复合年增长率为 6.14%。

千禧世代中，科技主导的个人成长平台的日益普及也有望对预测期内的市场成长产生正面影响。棕榈酰乙醇酰胺市场报告对市场进行了全面评估。它对关键细分市场、趋势、市场驱动因素、限制因素、竞争格局以及在市场中发挥重要作用的因素进行了全面的分析。

全球棕榈酰乙醇酰胺市场定义

棕榈酰乙醇酰胺是一种内源性脂肪酸酰胺，属于核因子促效剂类。人们已在体外和体内系统中透过外源性添加或施用化合物对 PEA 进行了研究。棕榈酰乙醇酰胺，也称为棕榈酰乙醇胺或N-2羟乙基棕榈酰胺，是一种天然存在的生物活性脂质，属于N-酰基乙醇胺（NAE）家族，作用于大麻素受体（CR2）并与神经系统的发炎细胞相互作用。慢性疼痛和神经病变疼痛是临床需求尚未被满足的疾病。 PEA 已在各种慢性和神经病变疼痛的动物模型上进行了测试。

PEA 在急性和持续性疼痛模型中的镇痛和镇痛作用似乎至少部分可以透过从头神经甾体合成来解释。在慢性肉芽肿性疼痛和发炎模型中，PEA 可以防止神经发生和发芽以及机械性异常疼痛，并且 PEA 可以抑制背根神经节激活，这是神经病变疼痛的压迫标誌。 PEA 作为镇痛和抗发炎分子的作用机制可能基于不同的方面。

全球棕榈酰乙醇酰胺市场概况

预计预测期内市场将大幅成长。推动市场成长的关键因素是神经病变疼痛、纤维肌痛、多发性硬化症 (MS) 和腕管综合症的发病率不断上升、疾病意识计划的加强（尤其是在新兴国家）以及治疗神经病变疼痛、多发性硬化症和腕管综合征的有效组合药物的开发。

此外，政府倡议的增加和健康意识的增强也是预计扩大全球市场的因素。对个人化药物和更好的诊断设施的需求不断增长可能会推动全球棕榈酰乙醇酰胺市场的发展。

预计在预测期内，製药商推出的新产品（例如非处方药）将显着成长。此外，消费者健康意识的增强和透过网路获得的医疗知识的提高也推动了非处方药的销售。

然而，严格的法规和因该化学物质对人体健康有害而引起的健康担忧是预计阻碍棕榈酰乙醇酰胺市场成长的主要因素。

目录

第一章全球棕榈酰乙醇酰胺市场介绍

• 市场概览
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章 棕榈酰乙醇酰胺全球市场预测

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型
• 价值链分析

第五章全球棕榈酰乙醇酰胺市场（按类型）

• 概述
• 纯度：99%以上
• 纯度：98%以上

6. 全球棕榈酰乙醇酰胺市场（依应用）

• 概述
• 生物学
• 製药

7. 全球棕榈酰乙醇酰胺市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 其他的
  • 拉丁美洲
  • 中东

8. 全球棕榈酰乙醇酰胺市场的竞争格局

• 概述
• 各公司市场排名
• 重点发展策略

第九章 公司简介

• Gihi Chemicals
• Cayman Chemical
• Synhwa Pharmachem
• PeaCURE
• TCI Chemicals
• STA
• Wuxi Cima Science

第十章 附录

• 相关调查

Palmitoylethanolamide Market Size And Forecast

Palmitoylethanolamide Market size was valued at USD 134.2 Billion in 2024 and is projected to reach USD 257.4 Billion by 2032, growing at a CAGR of 6.14% from 2026 to 2032.

The rising popularity of technology-driven platforms for self-growth amongst millennials is also expected to positively impact market growth during the forecast period. The Global Palmitoylethanolamide Market report provides a holistic evaluation of the market. The report offers comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Palmitoylethanolamide Market Definition

Palmitoylethanolamide (PEA) is an endogenous fatty acid amide, belonging to the class of nuclear factor agonists PEA has been studied in in vitro and in vivo systems using exogenously added or dosed compound; there is evidence that it binds to a nuclear receptor, through which it exerts a variety of biological effects, some related to chronic inflammation and pain. Palmitoylethanolamide (PEA), also called palmitoylethanolamine or N-2 hydroxyethyl palmitamide), belongs to the family of N-acylethanolamines (NAEs), naturally occurring, biologically active lipids that act on cannabinoid receptor (CR2) and interact with inflammatory cells in the nervous system. Chronic pain and neuropathic pain are indications for which there is high unmet need in the clinic. PEA has been tested in a variety of animal models for chronic and neuropathic pain.

The analgesic and antihyperalgesic effects of PEA in two models of acute and persistent pain seemed to be explained at least partly via the de novo neurosteroid synthesis. In chronic granulomatous pain and inflammation model, PEA could prevent nerve formation and sprouting, mechanical allodynia, and PEA inhibited dorsal root ganglia activation, which is a hallmark for winding up in neuropathic pain. The mechanism of action of PEA as an analgesic and anti-inflammatory molecule is probably based on different aspects.

Global Palmitoylethanolamide Market Overview

The market is expected to see a considerable amount of growth during the forecast period. The major factors that drive the growth of the market include increase in the incidence of neuropathic pain, fibromyalgia, multiple sclerosis (MS), carpal tunnel syndrome, rise in the number of disease awareness programs especially in the developing countries, and development of effective combination drug to treat neuropathic pain, multiple sclerosis and carpal tunnel syndrome.

Moreover, increase in government initiatives and rise in health awareness are the factors expected to augment the global market. Increase in demand for personalized medicines, and better diagnostic facilities are likely to propel the global palmitoylethanolamide market.

The new product launches by pharmaceutical manufacturers such as over-the-counter drugs are expected to witness substantial growth during the forecast period. Furthermore, the growing health awareness among consumers and rising medical knowledge with the help of the internet are driving the sales of over-the-counter drugs.

However, strict rules and health concerns arising from the harmful effects of chemicals on human well-being are the major factors that are expected to hamper palmitoylethanolamide market growth.

Global Palmitoylethanolamide Market Segmentation Analysis

The Global Palmitoylethanolamide Market is segmented based on Type, Application and Geography.

Palmitoylethanolamide Market, By Type

• Purity>99%
• Purity>98%

Palmitoylethanolamide Market, By Application

• Biology
• Pharmaceutical

Palmitoylethanolamide Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• North America is taking up the largest share in the Palmitoylethanolamide market and it is estimated that the region will continue dominating the market until next couple of years. Asia Pacific and Europe are also displaying a robust growth due to emergence of huge market growth opportunities in these regions.
• Key Players In Palmitoylethanolamide Market

The "Global Palmitoylethanolamide Market" study report will provide a valuable insight with an emphasis on the global market. The major players in the market are Gihi Chemicals, Cayman Chemical, Synhwa Pharmachem, PeaCURE, TCI Chemicals, STA, and Wuxi Cima Science.

• The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PALMITOYLETHANOLAMIDE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL PALMITOYLETHANOLAMIDE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL PALMITOYLETHANOLAMIDE MARKET, BY TYPE

• 5.1 Overview
• 5.2 Purity>99%
• 5.3 Purity>98%

6 GLOBAL PALMITOYLETHANOLAMIDE MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Biology
• 6.3 Pharmaceutical

7 GLOBAL PALMITOYLETHANOLAMIDE MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East

8 GLOBAL PALMITOYLETHANOLAMIDE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Gihi Chemicals
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Cayman Chemical
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Synhwa Pharmachem
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 PeaCURE
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 TCI Chemicals
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 STA
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Wuxi Cima Science
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments

10 Appendix

• 10.1 Related Research